News - UKKA

Following review, the MHRA has concluded that the available evidence no longer supports a positive benefit-risk balance for Avacopan Vifor (previously known as Tavneos), used in combination with rituximab or cyclophosphamide for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

The UK Kidney Association welcomes Ginny Quan and Stephen John as the new Co-Chairs of its Clinical Directors Group.

We are seeking a renal trainee to join the UKKA 'Writing to Kidney Patients' project, which aims to develop national, co-produced resources to make kidney clinic communication genuinely patient-centred rather than clinician- or GP-directed.

The latest version of the Home Dialysis Utility Reimbursement Calculator is now available, reflecting utility tariffs for July 2026 to March 2027.

The UK Kidney Association (UKKA) and the British Association for Paediatric Nephrology (BAPN) have submitted a joint response to the Medicines and Healthcare products Regulatory Agency (MHRA) consultation on its proposed Rare Disease Therapies Regulatory Framework, reflecting the views of the wider kidney community.

Vifor, which markets avacopan in the UK, has issued a safety communication, in agreement with the MHRA, advising that no new patients should be started on the medicine while the MHRA review is ongoing.